ReviewCancer cell international2025
The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling the Influence of Polyphenols on Mitogen-activated Protein Kinases in Cancer.Cell biochemistry and biophysics · 2026Review
- Mechanisms of Traditional Chinese Medicine-Derived Alkaloids in Colorectal Cancer Therapy: Molecular Targets, Preclinical Evidence, and Translational Prospects.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) ranks as the third most prevalent malignancy and the second leading cause of cancer-related mortality globally. Despite substantial advancements in CRC therapies over recent decades, drug resistance continues to pose a significant challenge in effective treatment. This comprehensive review investigates the role of long non-coding RNAs (lncRNAs) in the emergence of drug resistance in CRC. Specifically, we analyze the functions of lncRNAs, including HOTAIR and MALAT1, in key processes such as apoptosis, DNA damage response and repair, cancer stem cell regulation, and drug metabolism. By examining the structural and biogenetic characteristics of lncRNAs, this review elucidates their specific contributions to drug resistance. We provide novel insights into the therapeutic potential of targeting lncRNAs to mitigate drug resistance in CRC, thereby offering new perspectives on treatment strategies. Ultimately, this review highlights the clinical implications of lncRNA research, emphasizing their potential as targets for innovative therapeutic interventions in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.